Psoriasis is an autoimmune skin disease that generally
affects
1%–3% of the total population globally. Effective treatment
of psoriasis is limited because of numerous factors, such as ineffective
drug delivery and efficacy following conventional pharmaceutical treatments.
Nanofibers are widely being used as nanocarriers for effective treatment
because of their multifunctional and distinctive properties, including
a greater surface area, higher volume ratio, increased elasticity
and improved stiffness and resistance to traction, favorable biodegradability,
high permeability, and sufficient oxygen supply, which help maintain
the moisture content of the skin and improve the bioavailability of
the drugs. Similar to the extracellular matrix, nanofibers have a
regeneration capacity, promoting cell growth, adhesion, and proliferation,
and also have a more controlled release pattern compared with that
of other conventional therapies at the psoriatic site. To ensure improved
drug targeting and better antipsoriatic efficacy, this study formulated
and evaluated a tazarotene (TZT)-calcipotriol (CPT)-loaded nanofiber
and carbopol-based hydrogel film. The nanofiber was prepared using
electrospinning with a polyvinyl alcohol/polyvinylpyrrolidone (PVA/PVP)
K-90 polymeric blend that was later incorporated into a carbopol base
to form hydrogel films. The prepared nanofibers were biochemically
evaluated and in vitro and in vivo characterized. The mean diameters of the optimized formulation,
i.e., TZT-loaded polyvinyl alcohol/polyvinylpyrrolidone nanofiber
(TZT-PVA/PVP-NF) and TZT-CPT-loaded polyvinyl alcohol/polyvinylpyrrolidone
nanofiber (TZT-CPT-PVA/PVP-NF) were 244.67 ± 58.11 and 252.31
± 35.50 nm, respectively, as determined by scanning electron
microscopy, and their tensile strength ranged from 14.02 ± 0.54
to 22.50 ± 0.03 MPa. X-ray diffraction revealed an increase in
the amorphous nature of the nanofibers. The biodegradability studies
of prepared nanofiber formulations, irrespective of their composition,
showed that these completely biodegraded within 2 weeks of their application.
The TZT-CPT-PVA/PVP-NF nanofibers exhibited 95.68% ± 0.03% drug
release at the end of 72 h, indicating a controlled release pattern
and following Higuchi release kinetics as a best-fit model. MTT assay,
antioxidant and lipid profile tests, splenomegaly assessment, and
weight fluctuation were all performed in the in vitro as well as in vivo studies. We found that the TZT-CPT-PVA/PVP-NF-based
hydrogel film has high potential for antipsoriatic activity in imiquimod-induced
Wistar rats in comparison with that of TT-PVA/PVP-NF nanofibers.